PD1/PD-L1 inhibitors are monoclonal antibodies that specifically block membrane receptors that are involved in the immunosuppressive signaling pathway, thus unleashing the immune tolerance of tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment (TME) and invigorating endogenous antitumor response to tumor lesions (27). The gene discussed is PDCD1; the disease is neoplasm.